Additional file 2: of Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer

Additional file 16: of Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer

Tine Storebjerg (3468488)
Siri Strand (3468497)
Søren Høyer (3227682)
Anne-Sofie Lynnerup (3468491)
Michael Borre (130550)
Torben Ørntoft (3453632)
Karina Sørensen (3725155)

August 2018

Table S7. 5fC score (continuous and dichotomized) in univariate Cox regression analysis of BCR-free ...

Additional file 7: Figure S5. of High levels of 5-hydroxymethylcytosine (5hmC) is an adverse predictor of biochemical recurrence after prostatectomy in ERG-negative prostate cancer

Siri Strand (3468497)
Soren Hoyer (3468503)
Anne-Sofie Lynnerup (3468491)
Christa Haldrup (3468494)
Tine Storebjerg (3468488)
Michael Borre (130550)
Torben Orntoft (3468500)
Karina Sorensen (3468485)

October 2015

Flow chart illustrating the sample inclusion/exclusion process (malignant cores). A total of 552 PC ...

Additional file 8: Figure S6. of High levels of 5-hydroxymethylcytosine (5hmC) is an adverse predictor of biochemical recurrence after prostatectomy in ERG-negative prostate cancer

Siri Strand (3468497)
Soren Hoyer (3468503)
Anne-Sofie Lynnerup (3468491)
Christa Haldrup (3468494)
Tine Storebjerg (3468488)
Michael Borre (130550)
Torben Orntoft (3468500)
Karina Sorensen (3468485)

October 2015

Flow chart illustrating the sample inclusion/exclusion process (NM cores). A total of 301 PC patient...

Additional file 1: of Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer

Tine Storebjerg (3468488)
Siri Strand (3468497)
Søren Høyer (3227682)
Anne-Sofie Lynnerup (3468491)
Michael Borre (130550)
Torben Ørntoft (3453632)
Karina Sørensen (3725155)

August 2018

Figure S1. Flow chart illustrating the sample inclusion/exclusion process in malignant cores. A) 5mC...

Additional file 3: of Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer

Tine Storebjerg (3468488)
Siri Strand (3468497)
Søren Høyer (3227682)
Anne-Sofie Lynnerup (3468491)
Michael Borre (130550)
Torben Ørntoft (3453632)
Karina Sørensen (3725155)

August 2018

Figure S3. Correlations between 5mC score and clinicopathological parameters. A) In the full PC set ...

Additional file 5: of Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer

Tine Storebjerg (3468488)
Siri Strand (3468497)
Søren Høyer (3227682)
Anne-Sofie Lynnerup (3468491)
Michael Borre (130550)
Torben Ørntoft (3453632)
Karina Sørensen (3725155)

August 2018

Figure S5. Correlations between 5fC score and clinicopathological parameters. A) In the full PC set ...

Additional file 4: of Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer

Tine Storebjerg (3468488)
Siri Strand (3468497)
Søren Høyer (3227682)
Anne-Sofie Lynnerup (3468491)
Michael Borre (130550)
Torben Ørntoft (3453632)
Karina Sørensen (3725155)

August 2018

Figure S4. Correlations between 5hmC score and clinicopathological parameters. A) In the full PC set...

Additional file 6: of Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer

Tine Storebjerg (3468488)
Siri Strand (3468497)
Søren Høyer (3227682)
Anne-Sofie Lynnerup (3468491)
Michael Borre (130550)
Torben Ørntoft (3453632)
Karina Sørensen (3725155)

August 2018

Figure S6. Correlations between 5caC score and clinicopathological parameters. A) In the full PC set...

Additional file 18: of Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer

Tine Storebjerg (3468488)
Siri Strand (3468497)
Søren Høyer (3227682)
Anne-Sofie Lynnerup (3468491)
Michael Borre (130550)
Torben Ørntoft (3453632)
Karina Sørensen (3725155)

August 2018

Table S9. 5caC score (dichotomized) in univariate and multivariate Cox regression analysis of BCR-fr...

Additional file 8: of Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer

Tine Storebjerg (3468488)
Siri Strand (3468497)
Søren Høyer (3227682)
Anne-Sofie Lynnerup (3468491)
Michael Borre (130550)
Torben Ørntoft (3453632)
Karina Sørensen (3725155)

August 2018

Table S1B. Clinical characteristics for PC patients represented on the TMA. Data for RP patients for...

Additional file 14: of Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer

Tine Storebjerg (3468488)
Siri Strand (3468497)
Søren Høyer (3227682)
Anne-Sofie Lynnerup (3468491)
Michael Borre (130550)
Torben Ørntoft (3453632)
Karina Sørensen (3725155)

August 2018

Table S5. 5hmC score (continuous) in univariate and multivariate Cox regression analysis of BCR-free...

Additional file 17: of Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer

Tine Storebjerg (3468488)
Siri Strand (3468497)
Søren Høyer (3227682)
Anne-Sofie Lynnerup (3468491)
Michael Borre (130550)
Torben Ørntoft (3453632)
Karina Sørensen (3725155)

August 2018

Table S8. 5caC score (continuous) in univariate and multivariate Cox regression analysis of BCR-free...

Additional file 13: of Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer

Tine Storebjerg (3468488)
Siri Strand (3468497)
Søren Høyer (3227682)
Anne-Sofie Lynnerup (3468491)
Michael Borre (130550)
Torben Ørntoft (3453632)
Karina Sørensen (3725155)

August 2018

Table S4. 5mC score (continuous and dichotomized) in univariate Cox regression analysis of BCR-free ...

Additional file 15: of Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer

Tine Storebjerg (3468488)
Siri Strand (3468497)
Søren Høyer (3227682)
Anne-Sofie Lynnerup (3468491)
Michael Borre (130550)
Torben Ørntoft (3453632)
Karina Sørensen (3725155)

August 2018

Table S6. 5hmC score (dichotomized) in univariate and multivariate Cox regression analysis of BCR-fr...

Additional file 10: of Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer

Tine Storebjerg (3468488)
Siri Strand (3468497)
Søren Høyer (3227682)
Anne-Sofie Lynnerup (3468491)
Michael Borre (130550)
Torben Ørntoft (3453632)
Karina Sørensen (3725155)

August 2018

Table S1D. Clinical characteristics for PC patients represented on the TMA. Data for RP patients for...

Additional file 16: of Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer

Tine Storebjerg (3468488)
Siri Strand (3468497)
Søren Høyer (3227682)
Anne-Sofie Lynnerup (3468491)
Michael Borre (130550)
Torben Ørntoft (3453632)
Karina Sørensen (3725155)

August 2018

Table S7. 5fC score (continuous and dichotomized) in univariate Cox regression analysis of BCR-free ...

Additional file 7: Figure S5. of High levels of 5-hydroxymethylcytosine (5hmC) is an adverse predictor of biochemical recurrence after prostatectomy in ERG-negative prostate cancer

Siri Strand (3468497)
Soren Hoyer (3468503)
Anne-Sofie Lynnerup (3468491)
Christa Haldrup (3468494)
Tine Storebjerg (3468488)
Michael Borre (130550)
Torben Orntoft (3468500)
Karina Sorensen (3468485)

October 2015

Flow chart illustrating the sample inclusion/exclusion process (malignant cores). A total of 552 PC ...

Additional file 8: Figure S6. of High levels of 5-hydroxymethylcytosine (5hmC) is an adverse predictor of biochemical recurrence after prostatectomy in ERG-negative prostate cancer

Siri Strand (3468497)
Soren Hoyer (3468503)
Anne-Sofie Lynnerup (3468491)
Christa Haldrup (3468494)
Tine Storebjerg (3468488)
Michael Borre (130550)
Torben Orntoft (3468500)
Karina Sorensen (3468485)

October 2015

Flow chart illustrating the sample inclusion/exclusion process (NM cores). A total of 301 PC patient...

Additional file 1: of Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer

Tine Storebjerg (3468488)
Siri Strand (3468497)
Søren Høyer (3227682)
Anne-Sofie Lynnerup (3468491)
Michael Borre (130550)
Torben Ørntoft (3453632)
Karina Sørensen (3725155)

August 2018

Figure S1. Flow chart illustrating the sample inclusion/exclusion process in malignant cores. A) 5mC...

Additional file 3: of Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer

Tine Storebjerg (3468488)
Siri Strand (3468497)
Søren Høyer (3227682)
Anne-Sofie Lynnerup (3468491)
Michael Borre (130550)
Torben Ørntoft (3453632)
Karina Sørensen (3725155)

August 2018

Figure S3. Correlations between 5mC score and clinicopathological parameters. A) In the full PC set ...

Additional file 5: of Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer

Tine Storebjerg (3468488)
Siri Strand (3468497)
Søren Høyer (3227682)
Anne-Sofie Lynnerup (3468491)
Michael Borre (130550)
Torben Ørntoft (3453632)
Karina Sørensen (3725155)

August 2018

Figure S5. Correlations between 5fC score and clinicopathological parameters. A) In the full PC set ...

Additional file 4: of Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer

Tine Storebjerg (3468488)
Siri Strand (3468497)
Søren Høyer (3227682)
Anne-Sofie Lynnerup (3468491)
Michael Borre (130550)
Torben Ørntoft (3453632)
Karina Sørensen (3725155)

August 2018

Figure S4. Correlations between 5hmC score and clinicopathological parameters. A) In the full PC set...

Additional file 6: of Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer

Tine Storebjerg (3468488)
Siri Strand (3468497)
Søren Høyer (3227682)
Anne-Sofie Lynnerup (3468491)
Michael Borre (130550)
Torben Ørntoft (3453632)
Karina Sørensen (3725155)

August 2018

Figure S6. Correlations between 5caC score and clinicopathological parameters. A) In the full PC set...

Additional file 18: of Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer

Tine Storebjerg (3468488)
Siri Strand (3468497)
Søren Høyer (3227682)
Anne-Sofie Lynnerup (3468491)
Michael Borre (130550)
Torben Ørntoft (3453632)
Karina Sørensen (3725155)

August 2018

Table S9. 5caC score (dichotomized) in univariate and multivariate Cox regression analysis of BCR-fr...

Additional file 8: of Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer

Tine Storebjerg (3468488)
Siri Strand (3468497)
Søren Høyer (3227682)
Anne-Sofie Lynnerup (3468491)
Michael Borre (130550)
Torben Ørntoft (3453632)
Karina Sørensen (3725155)

August 2018

Table S1B. Clinical characteristics for PC patients represented on the TMA. Data for RP patients for...

Additional file 14: of Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer

Tine Storebjerg (3468488)
Siri Strand (3468497)
Søren Høyer (3227682)
Anne-Sofie Lynnerup (3468491)
Michael Borre (130550)
Torben Ørntoft (3453632)
Karina Sørensen (3725155)

August 2018

Table S5. 5hmC score (continuous) in univariate and multivariate Cox regression analysis of BCR-free...

Additional file 17: of Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer

Tine Storebjerg (3468488)
Siri Strand (3468497)
Søren Høyer (3227682)
Anne-Sofie Lynnerup (3468491)
Michael Borre (130550)
Torben Ørntoft (3453632)
Karina Sørensen (3725155)

August 2018

Table S8. 5caC score (continuous) in univariate and multivariate Cox regression analysis of BCR-free...

Additional file 13: of Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer

Tine Storebjerg (3468488)
Siri Strand (3468497)
Søren Høyer (3227682)
Anne-Sofie Lynnerup (3468491)
Michael Borre (130550)
Torben Ørntoft (3453632)
Karina Sørensen (3725155)

August 2018

Table S4. 5mC score (continuous and dichotomized) in univariate Cox regression analysis of BCR-free ...

Additional file 15: of Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer

Tine Storebjerg (3468488)
Siri Strand (3468497)
Søren Høyer (3227682)
Anne-Sofie Lynnerup (3468491)
Michael Borre (130550)
Torben Ørntoft (3453632)
Karina Sørensen (3725155)

August 2018

Table S6. 5hmC score (dichotomized) in univariate and multivariate Cox regression analysis of BCR-fr...

Additional file 10: of Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer

Tine Storebjerg (3468488)
Siri Strand (3468497)
Søren Høyer (3227682)
Anne-Sofie Lynnerup (3468491)
Michael Borre (130550)
Torben Ørntoft (3453632)
Karina Sørensen (3725155)

August 2018

Table S1D. Clinical characteristics for PC patients represented on the TMA. Data for RP patients for...

Additional file 16: of Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer

Tine Storebjerg (3468488)
Siri Strand (3468497)
Søren Høyer (3227682)
Anne-Sofie Lynnerup (3468491)
Michael Borre (130550)
Torben Ørntoft (3453632)
Karina Sørensen (3725155)

August 2018

Table S7. 5fC score (continuous and dichotomized) in univariate Cox regression analysis of BCR-free ...

Additional file 7: Figure S5. of High levels of 5-hydroxymethylcytosine (5hmC) is an adverse predictor of biochemical recurrence after prostatectomy in ERG-negative prostate cancer

Siri Strand (3468497)
Soren Hoyer (3468503)
Anne-Sofie Lynnerup (3468491)
Christa Haldrup (3468494)
Tine Storebjerg (3468488)
Michael Borre (130550)
Torben Orntoft (3468500)
Karina Sorensen (3468485)

October 2015

Flow chart illustrating the sample inclusion/exclusion process (malignant cores). A total of 552 PC ...

Additional file 8: Figure S6. of High levels of 5-hydroxymethylcytosine (5hmC) is an adverse predictor of biochemical recurrence after prostatectomy in ERG-negative prostate cancer

Siri Strand (3468497)
Soren Hoyer (3468503)
Anne-Sofie Lynnerup (3468491)
Christa Haldrup (3468494)
Tine Storebjerg (3468488)
Michael Borre (130550)
Torben Orntoft (3468500)
Karina Sorensen (3468485)

October 2015

Flow chart illustrating the sample inclusion/exclusion process (NM cores). A total of 301 PC patient...

Additional file 2: of Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer

Abstract

Extracted data

Additional file 2: of Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer

Abstract

Extracted data

Topics

Related items

Topics

Related items